TTA Archives 2005-2012

David Aylward, executive director of the mHealth Alliance, writes in the Harvard Business Review’s ‘Innovations in Health Care’ blog, focuses on the paradox of mHealth; it may be the future, but it’s supported by charity or loses money; it can reach millions but isn’t proven to be scalable. ‘We don’t understand the business models that will support real public private partnerships in the deployment and sustainability of mHealth systems.’ Sproxil is mentioned as a model in combining private interest–pharmaceutical sales–with public interest (the drug is genuine). Article.